Price
$15.64+1.49%Social Signal Score
Revenue
$8.92M-0.31%Company Profile
- CEO
- Kenneth Donald Fuller
- Sector
- Financial Services
- Industry
- Asset Management - Income
- Beta
- 0.96
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 2.56
Financials
Revenue
$8.92M-0.3%Net Income
$33.92M+68.9%EBITDA
$36.05M+455.0%Free Cash Flow
$4.08M-87.6%EPS (diluted)
$1.48+48.0%Shares Outstanding (diluted)
22.91M+27.4%Operating Expenses
$2.32MCash & Debt
$10.12MReturn of Capital
$19.26MDividend per Share
$0.13Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $54.77M | $-820.2K | $-0.04 |
| 2024 | $87.86M | $87.21M | $5.10 |
| 2023 | $7.03M | $25.31M | $1.48 |
| 2022 | $10.87M | $-3.03M | $-0.18 |
| 2021 | $69.05M | $68.67M | $3.83 |
| 2020 | $-21.97M | $-22.36M | $-1.24 |
| 2019 | $46.96M | $46.79M | $2.60 |
| 2018 | $2.82M | $2.44M | $0.14 |
| 2017 | $22.99M | $22.42M | $1.25 |
| 2016 | $13.15M | $22.69M | $1.26 |
| 2015 | $14.63M | $-52.73M | $-2.93 |
| 2014 | $25.00M | $53.15M | $2.96 |
| 2013 | $17.03M | $75.89M | $4.22 |
| 2012 | $17.90M | $40.16M | $2.23 |
Valuation
SCDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-44.83%Social Signal Score
Mentions (6)
- Newsseekingalpha.com·4d ago·Positive
SCD: Dividend-Growth Stocks Help This Fund Provide Investors With Real Income Growth (Upgrade) LMP Capital & Income Fund offers a 10.49% yield and merits consideration by income investors seeking inflation protection. SCD's dividend-growth equities and midstream partnerships can support real income through rising payouts and inflation-linked contracts. SCD's 22.23% energy exposure has supported performance, while its distribution rises 10.4% beginning in December.
View source ↗ - Newsglobenewswire.com·31d ago·Negative
…s from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKI New late-breaking data presented today at ASN Kidney Week 2026 QUELIMMUNE (SCD-PED) treatment group demonstrates statistically significant higher survival in the primary analysis at Day 60, Day 90, and at hospital discharge versus comparator cohort No device-related adverse events (AEs) occurred in patients treated with QUELIMMUNE DENVER, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporatio…
View source ↗ - Newsglobenewswire.com·46d ago·Negative
FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition Potentially accelerates development, assessment, and review for approval by FDA Sepsis impacts about 1.7 million U.S. adults annually and contributes to nearly one in three in-hospital deaths DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused…
View source ↗ - News (RSS)seekingalpha·81d ago·Neutral
SCD: High Midstream/Low Bond Exposure Is A Good Combination
View source ↗ - Newsseekingalpha.com·81d ago·Negative
SCD: High Midstream/Low Bond Exposure Is A Good Combination LMP Capital & Income Fund offers a 9.23% yield, emphasizing income and inflation protection via high allocations to MLPs and midstream energy equities. SCD's portfolio is differentiated by a 24.5% allocation to energy infrastructure, providing bond-like stability, inflation hedges, and higher yields than typical equity funds. Despite strong sector positioning, SCD underperformed the S&P 500 in recent months, but delivered a 9.16% total …
View source ↗ - 4chan /biz/biz·105d ago·Neutral
>>62577176 SCD
View source ↗
Insider trading
Open-market buys and sells by SCD officers and directors.
- Bought
- $655k
- Sold
- $327k
32 trades
8 trades
- Mason Peter Daniel Charlesbought
- Grillo Anthonybought
- Cronin Daniel Pbought
- Kamerick Eileen Abought
- Cronin Daniel Pbought
- Cronin Daniel Pbought
- Vanderlee Peterbought
- Cronin Daniel Psold
60 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SCD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
